Compare AstraZeneca plc (AZN) vs Valero Energy Corporation (VLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Valero Energy Corporation — how do they compare? AstraZeneca plc trades at $167.14 (market cap $253.13B), while Valero Energy Corporation trades at $301.57 (market cap $89.50B). The key difference: AstraZeneca plc is far larger — about 2.8× Valero Energy Corporation's market cap, and AstraZeneca plc pays the higher dividend (1.92%). Which is the better fit depends on your goals.
| AZN | VLO | |
|---|---|---|
Market Cap | $253.13B | $89.50B |
Sector | Health | Energy |
52-Week High | $209.48 | $301.43 |
52-Week Low | $137.44 | $131.77 |
Enterprise Value | $279.37B | $95.26B |
Dividend Yield | 1.92% | 1.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Valero Energy (VLO) trades at $295.79, up 5.38% in the last session, reflecting strong momentum amid bullish technical signals and positive earnings surprises. The stock's valuation metrics, including a P/E of 20.5 and P/S of 0.69, appear reasonable relative to historical levels, while profitability remains solid with a 17.72% ROE. Recent news highlights VLO's exposure to elevated refining margins and strong fuel demand, particularly benefiting its Gulf Coast operations.
The outlook for VLO is supported by robust refining fundamentals and a favorable analyst consensus, though risks include volatile energy markets and declining revenue trends. Upside potential exists if the company continues to exceed earnings expectations and capitalizes on tight product supplies, but investors should monitor margin pressures and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
